Summary of Puma Biotechnology (PBYI) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $56.5 million, with product revenue net at $53.6 million, up from $42 million in Q1 2026 and $49.2 million in Q2 2025.

Net Income: GAAP net income of $8.2 million ($0.16 per diluted share), compared to a net loss of $3.8 million in Q1 2026.

Non-GAAP Net Income: $10.1 million ($0.20 per basic share).

Royalty Revenue: $2.9 million, consistent with Q1 2026.

Cash Position: $93.9 million in cash, cash equivalents, and marketable securities.

Cash Burn: Approximately $9.7 million, up from $4 million in Q1 2026.

Gross to Net Adjustment: 27.9% in Q2 2026, slightly higher than 27% in Q1 2026.

2Strategic Updates and Business Highlights

Product Performance: NERLYNX sales showed strong growth, with 2.93 thousand bottles sold in Q2 2026, a 26% increase from Q1 2026.

Marketing Strategy: Focus on increasing awareness of NERLYNX in both early-stage and metastatic HER2-positive breast cancer.

Clinical Trials: Ongoing Phase II trials for alisertib in small cell lung cancer and HER2-negative ER-positive breast cancer, with plans to initiate a second trial (ALISCA-Lung-2) in Q3 2026.

Commercial Expansion: Continued efforts to enhance clinical education and engagement, particularly in the specialty distributor channel, which saw significant growth.

3Forward Guidance and Outlook

2026 Revenue Guidance: Anticipated net NERLYNX product revenue of $205 million to $209 million, up from previous guidance of $202 million to $206 million.

Q3 2026 Expectations: Projected NERLYNX product revenue net between $54 million and $56 million, with royalty revenues of $2 million to $3 million.

Long-Term R&D Plans: Management indicated potential for Phase III trials of alisertib in 2027, contingent on data from ongoing studies.

4Bad News, Challenges, or Points of Concern

Declining New Prescriptions: New prescriptions for NERLYNX decreased by approximately 6% compared to Q1 2026, raising concerns about future growth.

Inventory Management: Inventory decreased by 57 bottles in Q2 2026, indicating potential challenges in managing supply and demand.

Royalty Rate Risks: Future royalty revenues from China may be impacted by market share thresholds for generic versions of NERLYNX, potentially reducing expected income in late 2026 or 2027.

Increased Operating Expenses: Anticipated higher total operating expenses in 2026, particularly in R&D, which may pressure margins.

5Notable Q&A Insights

R&D Spending Trajectory: Management indicated that they could stagger Phase III trials for alisertib, maintaining a focus on positive net income while investing in R&D.

Business Development Opportunities: The company is open to acquiring both commercial and development-stage assets, emphasizing a flexible approach to oncology assets beyond just breast and lung cancer.

Financial Discipline: Management stressed their commitment to maintaining positive net income and controlling expenses, which has contributed to recent commercial success. Overall, Puma Biotechnology reported a strong quarter with significant revenue growth and a positive outlook, despite some challenges in prescription trends and potential future royalty income risks.